Biochemistry 81 , 15641577 (2016)
With regard to the substantial clinical improvement criterion, the applicant asserted that omidubicel represents a substantial clinical improvement over existing technologies because the totality of the data (up to 10-year follow-up) powers the evidence that omidubicel, which would be the first patient-specific advanced cellular therapy donor source, meets a high unmet treatment need for a diverse group of patients with serious, life-threatening hematologic malignancies and provides high quality stem cells, clinically meaningful and highly statistically significant clinical improvement, lower healthcare resource utilization, with an overall favorable benefit/risk profile
It also downregulated pro-inflammatory signaling through inhibition of NF-B, COX-2, and TRPV1, suggesting a dual antioxidant and anti-inflammatory action that supported both mucosal integrity and epithelial regeneration
It solves the fundamental problem of poor oral absorption of traditional glutathione and represents a major breakthrough in glutathione delivery technology
10.1016/S1472-6483(10)61170-4 140